

Kathleen SPRING, PhD, managing director since 2020 at Gesellschaft für Bioanalytik Münster e.V. (https://www.bioanalytik-muenster.de/_rubric/index.php?rubric=EN+Home) in Münster, Germany. Bioanalytik Münster is a non-profit organisation. It's a regional network which was initiated in 2000 by local universities, research centres, enterprises, transfer institutions and investors to promote science, research and education in the field of (nano) bioanalytics in Münster region. We provide a central communication and information platform for scientists, entrepreneurs, investors and members of the public who are interested in bioanalytics. Bioanalytik Münster was involved as a partner in the H2020 project NOBEL and we coordinated the H2020 project REFINE which both were initiated by the nanomedicine community. The goal of REFINE was to pioneer a regulatory science framework for the risk-benefit assessment of nanomedical products to provide support to the nanomedicine community helping them to reply to regulatory requests.

I hold a Diploma in Human Biology of the University of Greifswald (2007) and a PhD (2012) in Molecular Biology of the University of Montreal, Canada. Since 2017 I am part of Bioanalytik Münster and manage the organisation since 2020.